Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 7 | 2024 | 144 | 1.490 |
Why?
|
| Liver Transplantation | 5 | 2024 | 1177 | 0.580 |
Why?
|
| Colonoscopy | 3 | 2014 | 279 | 0.500 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 254 | 0.470 |
Why?
|
| Colonoscopes | 2 | 2011 | 13 | 0.470 |
Why?
|
| Adenoma | 2 | 2011 | 246 | 0.390 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 39 | 0.340 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 573 | 0.330 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 121 | 0.280 |
Why?
|
| Rifamycins | 1 | 2016 | 6 | 0.280 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.280 |
Why?
|
| Education, Medical, Graduate | 3 | 2024 | 390 | 0.280 |
Why?
|
| Esophageal Fistula | 1 | 2006 | 11 | 0.280 |
Why?
|
| Pericardial Effusion | 1 | 2006 | 20 | 0.270 |
Why?
|
| Cardiac Tamponade | 1 | 2006 | 20 | 0.270 |
Why?
|
| Liver Diseases | 3 | 2021 | 242 | 0.260 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 91 | 0.260 |
Why?
|
| Hepatitis C | 2 | 2021 | 170 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 599 | 0.230 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 332 | 0.220 |
Why?
|
| Antiviral Agents | 2 | 2021 | 475 | 0.220 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 311 | 0.210 |
Why?
|
| Curriculum | 3 | 2021 | 567 | 0.200 |
Why?
|
| United States | 8 | 2024 | 6955 | 0.190 |
Why?
|
| Viremia | 1 | 2021 | 49 | 0.190 |
Why?
|
| Internship and Residency | 3 | 2021 | 1041 | 0.190 |
Why?
|
| Gastroenterologists | 1 | 2021 | 31 | 0.190 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2020 | 16 | 0.180 |
Why?
|
| Donor Selection | 1 | 2021 | 74 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Internal Medicine | 2 | 2021 | 355 | 0.170 |
Why?
|
| Clinical Competence | 4 | 2021 | 780 | 0.170 |
Why?
|
| Faculty, Medical | 1 | 2021 | 185 | 0.170 |
Why?
|
| Middle Aged | 12 | 2021 | 25863 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2021 | 490 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 19 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 34 | 0.150 |
Why?
|
| Male | 15 | 2021 | 42251 | 0.150 |
Why?
|
| Humans | 22 | 2024 | 89063 | 0.140 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 410 | 0.140 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.130 |
Why?
|
| Adult | 11 | 2021 | 26507 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 418 | 0.130 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 59 | 0.130 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 237 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 390 | 0.120 |
Why?
|
| Liver Failure | 1 | 2015 | 67 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 93 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Education, Medical | 1 | 2017 | 243 | 0.120 |
Why?
|
| Female | 13 | 2021 | 46011 | 0.120 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 9 | 0.120 |
Why?
|
| Ammonia | 1 | 2014 | 38 | 0.120 |
Why?
|
| Hyperammonemia | 1 | 2014 | 13 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 96 | 0.120 |
Why?
|
| Glycerol | 1 | 2014 | 35 | 0.120 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 463 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 170 | 0.110 |
Why?
|
| Hospitalization | 2 | 2016 | 876 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2014 | 160 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 469 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 179 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2014 | 230 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 754 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 6288 | 0.100 |
Why?
|
| Hospitalists | 1 | 2014 | 135 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2014 | 299 | 0.090 |
Why?
|
| Ribavirin | 1 | 2010 | 40 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2014 | 385 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2010 | 226 | 0.090 |
Why?
|
| Adolescent | 2 | 2020 | 9237 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2010 | 129 | 0.090 |
Why?
|
| Aged | 8 | 2016 | 19077 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 684 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 358 | 0.080 |
Why?
|
| Time Factors | 4 | 2021 | 5320 | 0.080 |
Why?
|
| Career Choice | 2 | 2021 | 148 | 0.070 |
Why?
|
| Graft Survival | 2 | 2021 | 898 | 0.070 |
Why?
|
| Midodrine | 1 | 2016 | 4 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2016 | 9003 | 0.070 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 56 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 145 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2021 | 8203 | 0.070 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 60 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2021 | 314 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2021 | 850 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 107 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 848 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6777 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5466 | 0.050 |
Why?
|
| Incidence | 1 | 2016 | 1592 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1591 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 948 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1855 | 0.050 |
Why?
|
| Program Development | 1 | 2021 | 123 | 0.050 |
Why?
|
| Educational Status | 1 | 2021 | 194 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 2290 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1837 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 988 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 504 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 356 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 231 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1096 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 786 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 434 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 682 | 0.030 |
Why?
|
| Income | 1 | 2016 | 83 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 69 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3657 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 235 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 305 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 306 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 610 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 59 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
| Glutamine | 1 | 2014 | 79 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 447 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 386 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 461 | 0.030 |
Why?
|
| Urban Population | 1 | 2014 | 224 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 859 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 732 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 229 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2014 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 948 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 310 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1889 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1063 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1488 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 394 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 570 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 636 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 82 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 287 | 0.020 |
Why?
|
| Physicians | 1 | 2017 | 689 | 0.020 |
Why?
|
| Disposable Equipment | 1 | 2010 | 21 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 415 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1714 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2752 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11737 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1423 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1867 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2010 | 132 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 415 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1012 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 783 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 921 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2863 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1043 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1212 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 1848 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 27317 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 4273 | 0.010 |
Why?
|